Jazz Pharmaceuticals plc — Director's Dealing 2024

Feb 13, 2024

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2023-12-31

Reporting Person: Carr Patricia (SVP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-04	Ordinary Shares	S	50	$121.3947	Disposed	5986	Direct